Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Arrowhead has received a $500 million upfront payment in addition to $325 million through Sarepta’s purchase of Arrowhead common stock at $27.25 per share. Over the next five years, Arrowhead is set ...

Arrowhead has received a $500 million upfront payment in addition to $325 million through Sarepta’s purchase of Arrowhead common stock at $27.25 per share. Over the next five years, Arrowhead is set ...

Summary Financial Terms Upon closing, Arrowhead receives a $500 million upfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share. Arrowhead ...

PASADENA, Calif. - Arrowhead Pharmaceuticals, Inc. (NASDAQ: NASDAQ: ARWR), currently trading at $20.24 and showing an 8% gain over the past week, has finalized its licensing and collaboration ...

B.Riley analysts maintained their Buy rating on Arrowhead, emphasizing the company’s dominance in the siRNA therapeutics market. On the other hand, H.C. Wainwright raised Arrowhead’s stock price ...

Company News Published 02/10/2025, 08:37 AM 0 Arrowhead and Sarepta close $500 million licensing deal ARWR 2.57% ...

Summary Financial Terms Upon closing, Arrowhead receives a $500 million upfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share.

Summary Financial Terms Upon closing, Arrowhead receives a $500 million upfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share.

本文信息基于Arrowhead Pharmaceuticals, Inc.的新闻稿。 在其他近期新闻中，Arrowhead Pharmaceuticals宣布Douglas Ingram加入其董事会，这符合与Sarepta Therapeutics的投资者权利协议。Ingram自2017年起担任Sarepta的总裁兼首席执行官，为公司带来了丰富的生物制药行业经验。 在分析师报告方面，BMO ...

The financial terms of the deal are as follows: Arrowhead will receive a $500 million upfront payment along with $325 million from an equity investment by Sarepta at $27.25 per share (a 35% ...